Low, but not high, doses of an mGlu2/3 agonist were found to be helpful in patients in the early stages of schizophrenia (Kinon et al., 2015), suggesting that strategies to enhance mGlu3 signaling may help treat cognitive disorders. Here, GRM2 is linked to schizophrenia.